Browse diseases

…es, especially B-cell malignancies. The risk is highest in men. Myeloid malignancies tend to present closer to SSc diagnosis than lymphoid malignanc…

…ceptor (CAR)-T cells have achieved remarkable successes against B-cell malignancies but available autologous CD19.CAR therapies introduce patient-t…

…lonal antibody A3B1. Here, we report the case of a patient with B-cell acute lymphoblastic leukemia who required two infusions of ARI-0001 cells. Between the first…

…tyrosine kinase (BTK) inhibitor widely used in the treatment of B-cell malignancies. Its pharmacokinetics display marked inter- and intra-individua…

… antigen receptor (CAR) T-cell therapy is effective in treating B-cell malignancies, however relapse due to lack of CAR persistence and antigen-mod…

…owever, one of the prominent adverse effects of this therapy is B-cell aplasia, a condition characterized by prolonged depletion of normal B c…

…mited, largely due to the overlap of antigen expression between AML cells and normal hematopoietic cells. To identify novel, leukem…

… demonstrated potent anti-tumor efficacy in treating a range of B-cell malignancies. CAR-T constructs containing a CD28 costimulatory domain and CD…

…19-targeted CAR T-cell therapies have shown success in treating B-cell malignancies, with response rates up to 90%. However, up to half of patient’…

…n patients with relapsed or refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia, as recently reported in NEJM.1 These cohorts employed a 3-day …